Validea's guru fundamental report indicates Johnson & Johnson (JNJ) is highly rated by Partha Mohanram's P/B Growth Investor model, achieving an 88% score. This model, which identifies low book-to-market stocks with characteristics for sustained future growth and has demonstrated market outperformance, signals significant interest in JNJ based on its underlying fundamentals and valuation. While JNJ passed most of the model's growth criteria, it notably failed the Research and Development to Assets test.
Johnson & Johnson (JNJ) has been identified as a high-potential investment by Validea's P/B Growth Investor model, which is based on research by Partha Mohanram. The company achieved a score of 88%, a level that indicates strong interest from the quantitative strategy. This model specifically targets low book-to-market stocks that exhibit fundamental signs of sustained future growth. JNJ passed eight of the model's nine criteria, demonstrating strength in key areas including its Book/Market Ratio, Return on Assets (ROA), and Cash Flow from Operations relative to assets. Furthermore, the company shows operational stability, passing tests for low variance in both ROA and sales. The single notable failure was on the 'Research and Development to Assets' metric, which raises a specific point of concern for a large-cap firm in the Biotechnology & Drugs industry, where R&D is a crucial driver of long-term value.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
